- Citations, last 5 years
- 41
- Works, last 5 years
- 7
- h-index
- 10
- Scientists listed
- 0
- Grants since 2016
- 26
Grants received
2022–2026 · cooperative agreement · U01
Preclinical and early clinical development of a GABA-A a5 PAM
Sharon Rosenzweig-Lipson · AgeneBio (United States) · funded by National Institutes of Health
2022–2026 · cooperative agreement · U01
Preclinical and early clinical development of a GABA-A a5 PAM
Sharon Rosenzweig-Lipson · AgeneBio (United States) · funded by National Institutes of Health
2022–2026 · cooperative agreement · U01
Preclinical and early clinical development of a GABA-A a5 PAM
Kenneth G Payie · AgeneBio (United States) · funded by National Institutes of Health
2022–2026 · cooperative agreement · U01
Preclinical and early clinical development of a GABA-A a5 PAM
Sharon Rosenzweig-Lipson · AgeneBio (United States) · funded by National Institutes of Health
2022–2026 · cooperative agreement · U01
Preclinical and early clinical development of a GABA-A a5 PAM
Kenneth G Payie · AgeneBio (United States) · funded by National Institutes of Health
2022–2027 · cooperative agreement · U01
Preclinical and early clinical development of a GABA-A a5 PAM
Kenneth G Payie · AgeneBio (United States) · funded by National Institutes of Health
2019–2020 · research · R44
Structurally Diverse GABA-A ÃÂÃÂÃÂÃÂÃÂÃÂÃÂñ5 Positive Allosteric Modulators for Treatment of MCI due to AD
Sharon Rosenzweig-Lipson · AgeneBio (United States) · funded by National Institutes of Health
2019–2022 · research · R44
Structurally Diverse GABA-A a5 Positive Allosteric Modulators for Treatment of MCI due to AD
Sharon Rosenzweig-Lipson · AgeneBio (United States) · funded by National Institutes of Health
2019–2022 · research · R44
Structurally Diverse GABA-A a5 Positive Allosteric Modulators for Treatment of MCI due to AD
Sharon Rosenzweig-Lipson · AgeneBio (United States) · funded by National Institutes of Health
2019–2022 · research · R44
Structurally Diverse GABA-A a5 Positive Allosteric Modulators for Treatment of MCI due to AD
Sharon Rosenzweig-Lipson · AgeneBio (United States) · funded by National Institutes of Health
2019–2021 · research · Drug Discovery
In Vivo Characterization of a GABA-A alpha-5 Positive Allosteric Modulator
Sharon Rosenzweig-Lipson · AgeneBio (United States) · funded by Alzheimer's Drug Discovery Foundation
2018–2022 · research · R01
A Phase 3 Pivotal Trial of AGB101 to Slow Progression in MCI due to Alzheimer's Disease
Richard Charles Mohs · AgeneBio (United States) · funded by National Institutes of Health
2018–2022 · research · R01
A Phase 3 Pivotal Trial of AGB101 to Slow Progression in MCI due to Alzheimer's Disease
Richard Charles Mohs · AgeneBio (United States) · funded by National Institutes of Health
2018–2025 · research · R01
A Phase 3 Pivotal Trial of AGB101 to Slow Progression in MCI due to Alzheimer's Disease
Richard Charles Mohs · AgeneBio (United States) · funded by National Institutes of Health
2018–2025 · research · R01
A Phase 3 Pivotal Trial of AGB101 to Slow Progression in MCI due to Alzheimer's Disease
Richard Charles Mohs · AgeneBio (United States) · funded by National Institutes of Health
2018–2019 · cooperative agreement · UH3
Discovery/Development of GABA-A α5 Positive Allosteric Modulators for Treatment of MCI due to AD
Sharon Rosenzweig-Lipson · AgeneBio (United States) · funded by National Institutes of Health
2018–2022 · research · R01
A Phase 3 Pivotal Trial of AGB101 to Slow Progression in MCI due to Alzheimer's Disease
Richard Charles Mohs · AgeneBio (United States) · funded by National Institutes of Health
2018–2022 · research · R01
A Phase 3 Pivotal Trial of AGB101 to Slow Progression in MCI due to Alzheimer's Disease
Richard Charles Mohs · AgeneBio (United States) · funded by National Institutes of Health
2018–2020 · prize · Clinical
2018 Annual Goodes Prize for Excellence in Alzheimer’s Drug Discovery: Imaging Sub-study for the HOPE4MCI Phase 3 Trial
Michela Gallagher · AgeneBio (United States) · funded by Alzheimer's Drug Discovery Foundation
2017–2018 · cooperative agreement · UH2
Discovery/Development of GABA-A α5 Positive Allosteric Modulators for Treatment of MCI due to AD
Sharon Rosenzweig-Lipson · AgeneBio (United States) · funded by National Institutes of Health
2017–2022 · cooperative agreement · UH3
Discovery/Development of GABA-A α5 Positive Allosteric Modulators for Treatment of MCI due to AD
Sharon Rosenzweig-Lipson · AgeneBio (United States) · funded by National Institutes of Health
2017–2018 · research · R56
A Phase 3 pivotal trial of AGB101 to slow progression in MCI due to Alzheimer's Disease
Richard Charles Mohs · AgeneBio (United States) · funded by National Institutes of Health
2017–2023 · cooperative agreement · UH3
Discovery/Development of GABA-A ñ5 Positive Allosteric Modulators for Treatment of MCI due to AD
Sharon Rosenzweig-Lipson · AgeneBio (United States) · funded by National Institutes of Health
2017–2022 · cooperative agreement · UH3
Discovery/Development of GABA-A ñ5 Positive Allosteric Modulators for Treatment of MCI due to AD
Sharon Rosenzweig-Lipson · AgeneBio (United States) · funded by National Institutes of Health
2017–2018 · research · Drug Discovery
GABA-A alpha-5 Positive Allosteric Modulators for the treatment of aMCI due to AD.
Sharon Rosenzweig-Lipson · AgeneBio (United States) · funded by Alzheimer's Drug Discovery Foundation
2017–2018 · research · Clinical
Accelerating Manufacture of Clinical Supplies for Initiation of Patient Enrollment in the HOPE4MCI Phase 3 Trial (AgeneBio, AGB101)
Sharon Rosenzweig-Lipson · AgeneBio (United States) · funded by Alzheimer's Drug Discovery Foundation